Faruqi & Faruqi Reminds Sana Biotechnology Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 20, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sana To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $50,000 in Sana between March 17, 2023 and November 4, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, May 11, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sana Biotechnology, Inc. ('Sana' or the 'Company') (NASDAQ: SANA) and reminds investors of the May 20, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (2) SC291 in oncology, SC379, and SG299 were less promising than Defendants had led investors to believe; (3) in order to preserve cash and advance its more promising product candidates, Sana was likely to decrease funding for and/or discontinue SC291 in oncology, SC379, and SG299, as well as significantly reduce its headcount; (4) accordingly, Defendants overstated Sana's financial capacity to maintain its current operations and advance its existing product candidates; and (5) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
On October 10, 2023, during after-market hours, Sana issued a press release announcing that it 'will reduce near-term spend on its fusogen platform for in vivo gene delivery' and instead "[i]ncreas[e its] focus on [its] ex vivo cell therapy platform[,]' thereby 'postpon[ing] the planned SG299 IND' while 'decreas[ing] its expected forward operating burn.' Sana further disclosed a '29% headcount reduction' that, in tandem with the 'decreased expenses related to the fusogen platform[,]' would keep its '2024 operating cash burn . . . below $200 million[,]' thereby 'allowing [its] current cash position to extend further into 2025.' The same press release also quoted Defendant Steven D. Harr ('Harr'), Sana's President and Chief Executive Officer, as stating that "[w]e need to ensure that we have a financeable cost structure with . . . emerging opportunities factored in,' and that 'this strategic re-positioning enables us to deliver significant clinical data across multiple drug candidates with the current balance sheet.'
On this news, Sana's stock price fell $0.34 per share, or 8.95%, to close at $3.46 per share on October 11, 2023.
Then, on November 4, 2024, during after-market hours, Sana issued a press release announcing that it 'will suspend development of both SC291 in oncology and of SC379 . . . as it seeks partnerships for these programs' and instead 'increase its investment in its type 1 diabetes program with the cash savings from these changes[,]' thereby 'extend[ing] its expected cash runway into 2026.' The same press release also quoted Defendant Harr as stating that 'we need to ensure that we are directing our investments into the areas where we believe we can have the greatest impact for patients' and that "[t]his modified strategy will also help us reduce our cash burn but comes with the necessity of parting with some talented and valued colleagues.'
On this news, Sana's stock price fell $0.37 per share, or 9.84%, to close at $3.39 per share on November 5, 2024.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Sana's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Sana Biotechnology class action, go to www.faruqilaw.com/SANA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6b00ceb6-af61-48aa-9e35-79aaef8cfa67
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
37 minutes ago
- CBS News
UC Davis students can now bottle and sell their wines made on campus to support scholarships
UC Davis students can sell their own wines made to support scholarships UC Davis students can sell their own wines made to support scholarships UC Davis students can sell their own wines made to support scholarships DAVIS -- For 145 years, UC Davis has helped forge the future of the wine industry from the heart of its Yolo County campus. But now, for the first time, the university is finally allowed to bottle up and sell the wines made by students in its Department of Viticulture and Enology. It took a law change to get there and the creation of the nonprofit Hilgard631 for the state institution to legally sell wine. "That's 12 years in a nutshell. I'm glad we are here, able to celebrate this," said Professor David Block. Wednesday night, the department hosted an event celebrating the first-ever release and sale of the student creations. "They can share it with their friends and families, which is something they couldn't do before. So this is very exciting," said UC Davis head winemaker Leticia Chacon Rodriguez. Dozens of supporters showed up to taste-test the wines Wednesday, lining up after to purchase a bottle. "It's a good sauvignon. I like it. This is from a student?" asked one woman in surprise, tasting a delicious white wine. The magic happens from start to finish at UC Davis. Most of the grapes are grown at the vineyard on campus, and they are then fermented in the winery classroom as the students' visions come to life. Each pour represents a sense of accomplishment for those in the program. "There's a lot of pride and just excitement to share it," said student winemaker Naomi Morales. "If you're interested in the way that art and science collide, consider winemaking." Inside the teaching and research winery, their creations are made over the course of 10 weeks. Before this year, the wines made on campus had no sustainable future. "Unfortunately, before, the wine got just poured down the drain," said Ben Montpetit, chair of the Department of Viticulture and Enology. Now, the department is also able to teach students the business of winemaking too as they learn to design their own labels and sell their wines. It's helping raise a glass the the future for an industry seeing declining sales. "There's classes where they are given the freedom to do what they want and they really push the envelope. New varieties, new ways of making wine, new packaging," said Ben Montpetit. Hilgard631 handles public sales, now allowing the transfer of up to 20,000 gallons of department-made wines. The department bottled roughly 500 gallons of wine to sell for this release. All proceeds from the wine sales will support student scholarships. Bottles can be purchased in person only at the on-campus research winery at 631 Hilgard Rd. in Davis.
Yahoo
38 minutes ago
- Yahoo
How Trump's ‘Big Beautiful Bill' could affect oil and gas
MIDLAND, Texas (KMID/KPEJ) – President Trump's 'Big, beautiful bill' could pass by July 4th bringing tax cuts, border security, and a boost for Permian Basin jobs. Representative August Pfluger has championed several provisions in the bill to help the oil and gas industry. Energy provisions: Expedited LNG Exports (Section 41003) — Expedites approvals by deeming applications to non-free trade countries 'in the public interest' upon payment of a $1 million fee, eliminating a previously lengthy review process. This streamlining preserves existing legal and regulatory authorities while potentially reducing approval timelines from years to months. Natural Gas Permitting Reform (Section 41005) — Creates a voluntary expedited permitting pathway with guaranteed timelines, requiring agencies to complete reviews within one year of fee payment ($10M or 1% of project cost). If review deadlines are missed, applications are automatically approved, and legal challenges are limited. Strategic Petroleum Reserve Funding (Section 41008) — Provides a $2 billion appropriation for the Strategic Petroleum Reserve (SPR), including $218 million for cavern repairs, $1.32 billion for oil purchases, and directs the remaining funds to reverse prior mandated sales. This targeted investment strengthens U.S. energy security and reserve readiness. Environmental Provisions: Air Pollution Monitoring Limitation (Section 42105) — Repeals and rescinds unobligated funds from IRA Section 60105, which had allocated $281.5 million to the EPA for expanding air quality monitoring networks. This reduces the EPA's ability to identify new non-attainment zones, limiting additional regulatory burdens. Methane Emissions Program Delay (Section 42113) — Extends the timeline for the Methane Emissions Reduction Program charges by an additional 10 years. Healthcare provisions: Affordable Care Act Exchange Reforms (Section 44201) — Amends the Affordable Care Act's (ACA) definition of 'lawfully present' to exclude Deferred Action for Childhood Arrivals (DACA) recipients. This change counters the Biden Administration's May 2024 rule, which expanded ACA eligibility to include DACA recipients, a move with potential legal and financial implications. For more information on this legislative package, visit: Text – H.R.1 – 119th Congress (2025-2026): One Big Beautiful Bill Act | | Library of Congress Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Business Insider
39 minutes ago
- Business Insider
‘Don't Bet Against It': $4 Trillion in Sight for Nvidia Stock, Says Investor
Nvidia (NASDAQ:NVDA) has regained much of its shine over the last two months, catching fire once more with a bull run that has boosted its share price by some 50%. Confident Investing Starts Here: This sharp rebound came after a rare rough patch for the AI chipmaker earlier in 2025, when the stock struggled under the weight of tariff shocks, export restrictions, and concerns over reduced capex spending by hyperscalers. The tide began to turn as geopolitical tensions eased and major cloud players reaffirmed their investment plans, restoring confidence in the AI infrastructure boom. A strong earnings report and bullish guidance in late May further reinforced that momentum. However, even with the renewed optimism, not all signals are flashing green. Nvidia's revenue growth is beginning to decelerate – a likely outcome given its enormous scale – prompting some investors to question how much upside is still left. Could this be the point where enthusiasm gives way to caution? One investor, known by the pseudonym Cash Flow Venue, thinks the best course of action is to take a deep breath – and enjoy the ride. 'Let go of valuation concerns and wait for a $4 trillion+ valuation,' explains Cash Flow Venue, who urges investors to simply 'follow the money!' Looking at its recent Fiscal Q1 2026 earnings report, Cash Flow Venue cites the company's impressive year-over-year growth of 69% as a sign that Nvidia has no problem generating cash. Meanwhile, the company's EBITDA for the trailing twelve months has grown to some $91 billion, with the pace of the gains outpacing the rise in Nvidia's Enterprise Value. 'Nvidia's bears often forget that its valuation growth wasn't detached from the business growth. Even more, the business grew more dynamically than the valuation,' Cash Flow Venue noted. And there are plenty of drivers to boost additional growth, the investor hastens to add. With its top-tier hardware, CUDA software, and robust finances, Cash Flow Venue believes that CEO Jense Huang's optimism regarding Nvidia's future is certainly justified. With the pole position in the AI race and plenty of momentum on its side, it's an easy decision for this investor. 'A 'strong buy' business with the best capabilities to capitalize on the new 'industrial revolution,'' concludes Cash Flow Venue (To watch Cash Flow Venue's track record, click here) That's the gist on Wall Street as well. With 35 Buy, 4 Hold, and 1 Sell recommendations, NVDA continues to be a consensus Strong Buy. Its 12-month average price target of $172.36 indicates that despite its recent surge, analysts still see an upside of ~21% up ahead. (See NVDA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
